Key Developments: Abbott Laboratories (ABT)

ABT on New York Consolidated

42.11USD
22 Aug 2014
Price Change (% chg)

$-0.21 (-0.50%)
Prev Close
$42.32
Open
$42.22
Day's High
$42.33
Day's Low
$42.00
Volume
2,462,384
Avg. Vol
4,909,955
52-wk High
$43.27
52-wk Low
$32.70

Search Stocks

Latest Key Developments (Source: Significant Developments)

Abbott Laboratories Announces Dividend
Wednesday, 16 Oct 2013 07:44am EDT 

Abbott Laboratories announced an increase in the company's quarterly common dividend to $0.22 per share from $0.14 per share, representing an increase of 57%. The change takes effect with the dividend that will be paid on Feb. 15, 2014, to shareholders of record at the close of business on Jan. 15, 2014. This will mark the 42nd consecutive year Abbott has increased its dividend.  Full Article

Abbott Laboratories Reaffirms FY 2013 EPS Guidance
Wednesday, 16 Oct 2013 07:44am EDT 

Abbott Laboratories confirmed its fiscal 2013 ongoing earnings per share (EPS) guidance and expects EPS to be in the range of $1.98 to $2.04. Including these net specified items, projected EPS from continuing operations under Generally Accepted Accounting Principles (GAAP) would be $1.39 to $1.45 for fiscal 2013. According to I/B/E/S Estimates, analysts were expecting the Company to report EPS of $2.00 for fiscal 2013.  Full Article

Abbott Laboratories Declares 359th Consecutive Quarterly Dividend
Thursday, 12 Sep 2013 02:30pm EDT 

Abbott Laboratories announced that the Board has declared a quarterly common dividend of USD0.14 per share. This marks the 359th consecutive quarterly dividend to be paid by Abbott since 1924. The cash dividend is payable Nov. 15, 2013, to shareholders of record at the close of business on Oct. 15, 2013.  Full Article

Abbott Laboratories Completes Acquisition Of IDEV Technologies
Wednesday, 21 Aug 2013 09:00am EDT 

Abbott Laboratories announced that it has completed its acquisition of IDEV Technologies, a privately held company focused on developing medical devices for use by interventional radiologists, vascular surgeons and interventional cardiologists.  Full Article

Abbott Laboratories Completes Acquisition of OptiMedica
Monday, 19 Aug 2013 09:30am EDT 

Abbott Laboratories announced that it has completed its acquisition of OptiMedica Corporation, a privately-held, Silicon Valley-based ophthalmic device company. Abbott acquired OptiMedica for $250 million, net of cash. Additional amounts totaling up to $150 million will be payable upon completion of certain development, regulatory and sales milestones.  Full Article

Abbott Laboratories Among Companies Fined for Price Fixing in China-Reuters
Tuesday, 6 Aug 2013 08:00pm EDT 

Reuters reported that China fined six companies, including Abbott Laboratories a total of USD 110 million following an investigation into price fixing and anti-competitive practices by foreign baby formula makers. The other companies penalised were Danone SA, Dutch dairy cooperative FrieslandCampina, Mead Johnson Nutrition Co, Fonterra and Hong Kong-listed Biostime International Holdings.  Full Article

Abbott Laboratories Reaffirms FY 2013 EPS Guidance
Wednesday, 17 Jul 2013 07:44am EDT 

Abbott Laboratories confirmed its fiscal 2013 ongoing earnings per share (EPS) guidance and expects EPS to be in the range of $1.98 to $2.04. Including these net specified items, projected EPS from continuing operations under Generally Accepted Accounting Principles (GAAP) would be $1.39 to $1.45 for fiscal 2013. According to I/B/E/S Estimates, analysts were expecting the Company to report EPS of $2.01 for fiscal 2013.  Full Article

Abbott Laboratories to Acquire IDEV Technologies
Monday, 15 Jul 2013 10:50am EDT 

Abbott Laboratories announced that it has entered into an agreement to purchase IDEV Technologies, a privately held company focused on developing medical devices for use by interventional radiologists, vascular surgeons and cardiologists. Under the terms of the agreement, Abbott will acquire all outstanding equity of IDEV Technologies for $310 million net of cash and debt. IDEV Technologies is headquartered in Webster,Texas. The transaction is expected to close by the end of the year. The transaction is subject to customary closing conditions, including antitrust clearances.  Full Article

Abbott Laboratories Enters Laser Cataract Surgery Market Through Acquisition Of Optimedica Corporation
Monday, 15 Jul 2013 08:30am EDT 

Abbott Laboratories announced that it has entered into an agreement to purchase OptiMedica Corporation, a privately held, Silicon Valley-based ophthalmic device company. Under the terms of the agreement, Abbott will acquire OptiMedica for $250 million, net of cash, plus additional payments totaling up to $150 million upon completion of certain development, regulatory or sales milestones. The transaction is expected to close by the end of the year and will not impact Abbott's ongoing full-year 2013 earnings-per-share guidance.  Full Article

Abbott Laboratories Announces New $3 Billion Share Repurchase Program; Declares Dividend
Friday, 14 Jun 2013 12:22pm EDT 

Abbott Laboratories announced that its board of directors has approved a new share repurchase program and declared a quarterly common dividend. Abbott's board has authorized the repurchase of up to $3 billion of the corporation's common stock. The program replaces the previous $5 billion program that was announced in October 2008 and was recently completed. The purchases may be made from time to time as market conditions warrant and subject to regulatory considerations. The board also declared a quarterly common dividend of $0.14 per share. The cash dividend is payable August 15, 2013, to shareholders of record at the close of business on July 15, 2013.  Full Article

Fitch Maintains CFR's IDRs on Rating Watch Positive

(The following statement was released by the rating agency) CHICAGO, August 29 (Fitch) Fitch Ratings maintains CFR Pharmaceuticals S.A. and its subsidiary CFR International SpA on Rating Watch Positive in anticipation of their acquisition by Abbott Investments Luxembourg S.A.R.L., a subsidiary of Abbott Laboratories (Abbott; rated 'A+' by Fitch). A complete list of rating actions follows at the end of this press release. KEY RATING DRIVERS Rating Watch Positive Fitch initially placed the co

Search Stocks